We're #hiring a new Senior Research Associate in Cambridge, Massachusetts. Apply today or share this post with your network.
About us
Thymmune is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. The company's cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune diseases. Thymmune is based in Cambridge, MA. For more information, visit www.thymmune.com.
- Website
-
https://www.thymmune.com/
External link for Thymmune Therapeutics
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
Locations
-
Primary
Get directions
238 Main St
Cambridge, Massachusetts 02142, US
Employees at Thymmune Therapeutics
-
Ayis Antoniou
Entrepreneur/mentor/experienced, impactful, innovative leader/strategic advisor looking to connect with early-stage companies in bio-tech
-
Stan Wang, MD, PhD
CEO & Founder at Thymmune Therapeutics
-
Meg Wood
SVP of Ventures and BD, Managing Director
-
Qiumei Du
Senior Scientist
Updates
-
We're #hiring a new Research Associate, Pluripotent Stem Cell Biology in Cambridge, Massachusetts. Apply today or share this post with your network.
-
It was a pleasure serving on a panel at last week's BIO International Convention with Advanced Research Projects Agency for Health (ARPA-H) Deputy Director Susan Coller Monarez, Mission Office Directors Wade Shen & Jason R., and Optosurgical LLC CEO Yoseph Kim! At Thymmune Therapeutics, doing business with ARPA-H has been a fast, flexible, and efficient collaboration in moving our approach towards patients in need.
-
We're #hiring a new Research Associate, Pluripotent Stem Cell Biology in Cambridge, Massachusetts. Apply today or share this post with your network.
-
Thymmune Therapeutics reposted this
‘We want to give everyone a new thymus to reboot their immune system’ Thymmune Therapeutics founder Stan Wang, MD, PhD says ARPA-H funding will bring ‘off-the-shelf’ thymus rejuvenation technology to human clinical trials. #longevity #immune #rejuvenation
‘We want to give everyone a new thymus to reboot their immune system’
https://longevity.technology
-
The first significant investment into the internet was done by ARPA in the 1960s. Today, ARPHA-H, a new government org focused on health R&D, just made its first ever investment into Thymmune Therapeutics, our featured startup for E18 of S³.
-
As the first biotech startup funded by Wellcome Leap in its inaugural HOPE program, we at Thymmune are proud to be continuing the work at scale as the first biotech funded through the Advanced Research Projects Agency for Health (ARPA-H)'s Open BAA. The focused, ambitious, and rapid pace of the work we did as part of HOPE with Annie Moisan and Cara Buchanan was critically enabling for Thymmune. Wellcome Leap executes the ARPA model at global scale--and it was fantastic preparation as we enter this next phase of advancing our cell therapy. We look forward to progressing our approach to providing a new thymus to patients in need.
-
Congratulations again to Stan Wang, MD, PhD, CEO of Thymmune Therapeutics and Boston Business Journal 40 Under 40 honoree!
-
-
We're #hiring a new Research Associate, Pluripotent Stem Cell Biology in Cambridge, Massachusetts. Apply today or share this post with your network.
-
We're #hiring a new Scientist, Immunology, Animal Studies, and Aging in Cambridge, Massachusetts. Apply today or share this post with your network.